abstract BACKGROUND: Stevens-Johnson syndrome (SJS) is an uncommon, sporadic disease and outbreaks are rare. In November 2013, an outbreak of SJS was identified at Children's Hospital Colorado.
Stevens-Johnson syndrome (SJS) is
an immune-mediated disease characterized by a prodromal illness followed by severe mucocutaneous symptoms. 1 SJS can result in severe morbidity from scarring of mucosal surfaces, leading to blindness as well as urethral and esophageal strictures. The case-fatality rate for SJS is ∼10% in adults 2,3 but may be less in children; up to 50% may develop long-term sequelae. [4] [5] [6] Although the pathogenesis is incompletely understood, SJS and its more severe form, toxic epidermal necrolysis (TEN), are the result of an inflammatory response that results in keratinocyte necrosis and perivascular lymphocyte infiltration. 7 SJS was classically ascribed to a medication hypersensitivity reaction; however, infectious etiologies, including Mycoplasma pneumoniae (Mp), are increasingly recognized as inciting agents. [8] [9] [10] SJS has an estimated incidence of 1 to 7 cases per million person-years, [11] [12] [13] [14] [15] although pediatric rates are not well described because of a lack of published information. Epidemiologic clusters of SJS are exceptionally rare and have been associated with both medications (including mebendazole and metronidazole) 16 and infection such as Mp. 9, 17, 18 SJS attributed to Mp represents only a small fraction of overall cases, and published information about the clinical characteristics of this condition is limited to small case series.
In November 2013, physicians observed an increase in the number of children admitted to a tertiary care children's hospital with SJS associated with Mp infection. This clinical observation prompted a formal investigation, in collaboration with the Colorado Department of Public Health and Environment and Centers for Disease Control and Prevention (CDC), to improve our understanding of the epidemiology and clinical manifestations of Mp-associated SJS. This article characterizes the largest reported pediatric SJS outbreak and describes the clinical manifestations of Mp-associated SJS.
METHODS Setting
Children's Hospital Colorado (CHCO) is a 553-bed, tertiary care hospital with 17 646 admissions in 2013. It is the primary children's referral hospital for the state of Colorado, with a catchment population of 1.2 million children, and the surrounding states.
Case Definitions
A case of SJS during the outbreak was defined as a patient with an International Classification of Diseases, Ninth Revision (ICD-9) code for SJS, SJS-TEN, or TEN and meeting clinical criteria, including involvement of skin and at least 2 mucus membranes. 19 Epidemiologic criteria for outbreak-associated cases of SJS were age 5 to 21 years and admission to CHCO between September 1 and November 30, 2013. The age range was selected to reflect both the patient population treated at CHCO and the population susceptible to Mp-associated SJS (extremely rare in infants, young children, and adults past middle age). The study period was selected to reflect both the long incubation period of Mp (2-4 weeks) and the time period during which clinicians reported an increase in SJS cases at CHCO. Additional hospitalized SJS cases were identified retrospectively to October 2008, when ICD-9 codes for SJS first came into use, to further characterize the spectrum of disease.
SJS cases were classified according to the likelihood of Mp as the underlying etiology. To be considered a "confirmed case," a patient required a positive Mp result by polymerase chain reaction (PCR) on a respiratory tract specimen and no alternative etiology (eg, medication effect) identified. A "probable case" required positive Mp immunoglobulin (Ig)M (with or without positive IgG) with no alternative etiology more likely. A "possible case" was defined as an SJS patient with positive Mp laboratory testing (PCR or IgM) and an alternative etiology or symptoms consistent with Mp infection (radiographic pneumonia or fever and 1 of cough, shortness of breath, or hypoxia), but laboratory testing was negative or not performed. All others were considered non-Mp-associated cases.
Laboratory Methods
Patients with SJS were tested for infectious etiologies at the discretion of their treating clinicians, usually at the time of hospital presentation. Testing for Mp infection at CHCO included PCR performed on throat swab specimens sent to a reference laboratory (Focus Diagnostics Inc, Cypress, CA), a respiratory pathogen PCR performed on the FilmArray (FA) system (BioFire Diagnostics, Salt Lake City, UT), 20 
Ethical Approval
Outbreaks are reportable public health conditions in Colorado; as such, this outbreak investigation was not considered to be research that required review by an institutional review board or informed consent from the patients.
RESULTS

Outbreak Investigation
Eight SJS cases were admitted to CHCO between September 1 and November 30, 2013 (Fig 1) . All had evidence of Mp infection; 5 (63%) were classified as confirmed Mpassociated SJS on the basis of positive Mp PCR results, and 3 (38%)
were classified as possible Mpassociated SJS on the basis of clinical symptoms (Table 1) . One child (13%) was also positive for herpes simplex virus (HSV) by PCR on an oral swab. Of 6 children tested by FA, 2 (33%) had a virus detected (1 rhino/enterovirus, 1 parainfluenza virus type 4) in addition to Mp. Both probable Mp-associated SJS cases in the outbreak were taking preceding medications: 1 (13%) child was taking trimethoprimsulfamethoxazole for a sinus infection (starting 8 days before lesion onset) and azithromycin for pertussis postexposure prophylaxis (starting 13 days before lesion onset); 1 child was taking azithromycin for pneumonia (starting 6 days before lesion onset). Three (38%) children reported household contacts with respiratory symptoms. Of the 8 children, 5 (63%) were male and the median age was 11.5 years (range 8-16 years; Table 1 ).
All 8 children had oropharyngeal mucositis, 7 (88%) had conjunctival involvement, and 5 (63%) had vaginal/penile involvement ( Table 2 ). All patients had skin involvement, and the median number of sites (head, trunk, arms, legs) involved was 2.5 (range 1-4), although the severity of skin involvement overall was mild. Mucosal disease severity varied, with 4 (50%) receiving amniotic membrane grafting to eyes, 2 (25%) requiring ICU admission, and 6 (75%) needing nasogastric feeds or total parenteral nutrition. One (13%) child did not require any of these interventions. All 8 children received azithromycin, including 2 (25%) who were put on a prolonged course (.1 year) with concern for development of bronchiolitis obliterans. All were discharged well.
The CUSUM exceeded the precalculated threshold in November 2013, indicating that an outbreak of SJS cases occurred during the study period (September 1 to November 30, 2013) (Fig 1) . This finding also correlated with a large increase in Mp disease in the community. 25 
Mp Characterization
Banked Mp PCR-positive respiratory specimens were available from 48 children (including 5 children with outbreak-associated SJS and 43 with non-SJS disease) admitted to CHCO between January 1 and December 13, 2013, and were submitted to the CDC laboratory for further testing. Of these, 46 (96%) were confirmed as Mp-positive by the CDC PCR. Five MLVA types were observed among the specimens tested, including 3 among the 5 Mp-associated SJS cases: 1 of type 3-5-6-2, 2 of type 3-6-6-2, and 2 of type 4-5-7-2. Forty-three specimens (93%) were macrolide susceptible, and 3 (7%) were macrolide resistant. All Mp isolates from the SJS cases were macrolide susceptible.
Case-Control Analysis
Twenty-two episodes of SJS were identified as confirmed (n = 8), probable (n = 9), or possible (n = 5) Mp-associated, and 23 were identified as non-Mp-associated between October 1, 2008, and November 30, 2013 ( Table 3 minimal skin involvement, with an atypical "psittacosis-like" pneumonia. 10, 17, 19, 32 Furthermore, a recent, systematic review of the literature suggests that Mpassociated disease might be a clinical entity distinct from druginduced SJS. These authors proposed renaming this entity to Mp-induced rash and mucositis due to the minimal cutaneous involvement. 33 Our data support this finding of mucositispredominant disease, but in contrast to the conclusion of their review, the majority of our patients had severe disease necessitating prolonged hospitalizations and surgical intervention. Outbreaks of SJS are exceedingly rare with only 2 confirmed Mp-associated SJS clusters reported (10 cases total). 9,18 Although 5 children in our outbreak had positive Mp testing by PCR, all 8 met Mp-associated SJS case definitions and had additional findings supportive of an Mp etiology including radiographic pneumonia, elevated ESR, and history of exposure to household contacts with respiratory symptoms.
We offer 2 likely explanations for the recent outbreak. Our initial hypothesis was that a new Mp strain with a greater predisposition to induce SJS was circulating in the community. In support of this hypothesis, of the 5 Mp-SJS cases with available MLVA typing, 3 had a similar subtype, despite the fact that multiple MLVA subtypes were circulating in the community during this time. These subtypes, however, have not been previously associated with SJS disease and have been circulating across the United States for several years. 34 MLVA typing may also not be a reliable measure of clonality because multiple MLVA types may circulate in a single outbreak setting. 35 A second, more likely hypothesis is that there was a large outbreak of Mp in the community, which resulted in an increased rate of SJS due to an overall increased rate of exposure to Mp. This is supported by a community-wide investigation, which found a significant increase in atypical pneumonia diagnoses, macrolide prescriptions, and positive Mp testing. 25 Epidemics of Mp pneumonia are known to occur in 3-to 7-year cycles, 36 and Mp outbreaks have been previously observed in Colorado. 37 The clinical spectrum of disease in our pediatric outbreak and retrospective case-control study was similar to previous published case series of Mpassociated SJS. 8, 38, 39 Prodromal respiratory illness and fever were common. 8 Mucositis was predominant, with multiple mucus membranes involved, including ocular lesions. 38, 39 We observed a less severe distribution of skin involvement in the Mp-SJS group. Mucous membrane involvement was similar between groups, but severity and distribution were more difficult to quantify. Other studies also report less severe skin manifestations and organ dysfunction in patients with Mp-associated SJS, including some who describe a Mp-associated SJS-like disease with mild or no skin lesions, referred to as Mp-associated mucositis (MPAM), 10,40-43 atypical SJS, 9,44-46 incomplete SJS, 47 or Fuch syndrome. [48] [49] [50] Several of our SJS cases had previous episodes of SJS, as well as previous mucositis-only episodes that did not meet our case definitions. 51 Many experts consider these various exanthemas separate manifestations along a spectrum of SJS. 9, 52, 53 In general, skin involvement is common with Mp infection, with Mp pneumonia said to be associated with rash in 3% to 33% of patients. 54, 55 Mp has also been cultured from blisters of patients with SJS. 56 Several of our patients with Mpassociated SJS had severe disease, necessitating ICU admission, ventilator support, amniotic membrane grafting, and other supportive measures. Although data were limited, it was not clear that treatment with intravenous immunoglobulin (IVIG), corticosteroids, or macrolide antibiotics led to improved outcome, which is consistent with previous literature. 7 The significant differences between Mp-associated SJS and non-Mpassociated SJS are not surprising. Mp is highly transmissible 57 
